Valeo Pharma Inc. Canadian Securities Exchange

VPH

CA91915B1085

Pharmaceuticals

Delayed Canadian Securities Exchange Other stock markets 01:27:37 29/03/2022 am IST			5-day change	1st Jan Change
0.66 ^CAD	-.--%		+1.54%	-10.81%

25/04	Transcript : Valeo Pharma Inc. - Shareholder/Analyst Call
22/03	Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors	CI

Valeo Pharma Inc. Reaffirms Revenues Guidance for 2022

September 23, 2021 at 06:00 pm IST

Valeo Pharma Inc. is maintaining earlier guidance of the doubling of revenues from 2021 and the company expects at least the same for 2022.

Latest news about Valeo Pharma Inc.

Transcript : Valeo Pharma Inc. - Shareholder/Analyst Call	25/04
Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors	22/03	CI
Transcript : Valeo Pharma Inc., Q1 2024 Earnings Call, Mar 15, 2024	15/03
Valeo Pharma Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	15/03	CI
Valeo Pharma Inc. Announces Board Changes	13/02	CI
Valeo Pharma Brief: Notes Sagard credit facility amended to provide for early repayments and liquidity requirements in fiscal 2024	03/02	MT
Valeo Pharma Brief: Says Proceeds from reimbursement to be used for debt reduction purposes	03/02	MT
Valeo Pharma Brief: Adding SIMBRINZA remains under Valeo Pharma exclusive promotion and distribution	03/02	MT
Valeo Pharma Brief: Says Original commercialization and supply agreement amended following global divestment of XIIDRA	03/02	MT
Valeo Pharma Brief: Amending Agreement With Novartis Pharmaceuticals Canada For XIIDRA In Canada, and Credit Facility With Sagard Healthcare Royalty Partners, LP	03/02	MT
Valeo Pharma Amends Agreement with Novartis Pharmaceuticals Canada for (Pr)XIIDRA in Canada	03/02	CI
Valeo Pharma Inc. Amends Credit Facility with Sagard Healthcare Partners, LP	03/02	CI
Transcript : Valeo Pharma Inc., Q4 2023 Earnings Call, Jan 30, 2024	30/01
Valeo Pharma's Q4'23 Net Loss Holds Steady YOY	30/01	MT
Valeo Pharma Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	30/01	CI
North American Morning Briefing : Cautious Start to Fully-Booked Week	29/01	DJ
LSL Pharma Group Appoints Luc Mainville as Chief Financial Officer	04/12	MT
Valeo Pharma Announces Organizational Changes and Cost Reduction Initiatives; Shares Jumped Near 30% Friday	20/11	MT
Valeo Pharma Inc. Announces Chief Financial Officer Changes	20/11	CI
Valeo Pharma Brief: Expected to generate annual savings exceeding $2 million	20/11	MT
Valeo Pharma Brief: Announcing Organizational Changes and Cost Reduction Initiatives	20/11	MT
Valeo Pharma Inc. Announces Appointment of Mr. Richard Lajoie to Board of Directors	07/11	CI
Valeo Pharma Entered Into $5 Million Credit Facilty Agreement With Accord Financial Inc.	27/23/27	MT
Valeo Pharma Enters into $5 Million Credit Facility Agreement with Accord Financial Inc	27/23/27	CI
Valeo Pharma's Fiscal Q3 Loss Widens, Revenue Grows; Up 3.5%	14/23/14	MT

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.

Sector

Pharmaceuticals

Calendar

04/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Valeo Pharma Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.1 CAD

Average target price

0.5 CAD

Spread / Average Target

+400.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+34.00%	664B
NOVO NORDISK A/S	+29.29%	567B
JOHNSON & JOHNSON	-7.75%	354B
MERCK & CO., INC.	+18.53%	330B
ABBVIE INC.	+4.95%	286B
ASTRAZENECA PLC	+13.79%	234B
NOVARTIS AG	+4.93%	199B
ROCHE HOLDING AG	-9.78%	196B
AMGEN INC.	-4.89%	148B

Other Pharmaceuticals

Valeo Pharma Inc. Canadian Securities Exchange

Equities

VPH

CA91915B1085

Pharmaceuticals

Valeo Pharma Inc. Reaffirms Revenues Guidance for 2022

Latest news about Valeo Pharma Inc.

Chart Valeo Pharma Inc.

Company Profile

Income Statement Evolution

Ratings for Valeo Pharma Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals